Trethera Corp

Trethera Corp, based in Sherman Oaks, CA, is a biotechnology company focused on developing innovative treatment approaches for solid tumors and autoimmune diseases. Leveraging insights into metabolic pathways, their lead product candidate, TRE-515, targets nucleotide metabolism to inhibit cancer cell growth while potentially addressing immune system dysregulation in autoimmune disorders.

By strategically inhibiting the enzyme dCK, Trethera aims to disrupt nucleotide biosynthesis in cancer cells, offering a promising therapeutic strategy for specific tumor types and potential combination therapies. Their research efforts have garnered attention for their potential impact on diseases like multiple sclerosis and Crohn's disease, highlighting a commitment to advancing precision medicine in oncology and autoimmune conditions.

Generated from the website